Glenmark Pharmaceuticals’s its South African arm has signed a 10-year marketing and distribution rights agreement with MeyerZall Laboratories that will help in expanding its topical dermatology portfolio.

Glenmark’ portfolio will now  offer one of the widest topical dermatology baskets in the Glenmark Pharmaceuticals Ltd (GPL) today said its South African arm has signed a 10-year marketing and distribution rights agreement with MeyerZall Laboratories that will help in expanding its topical dermatology portfolioSouth African market.

Therapeutic areas covered by this distribution agreement include Psoriasis, Fungal infections of the skin and inflammation with the following products now falling into the Glenmark portfolio; Linotar Gel 1, Covarex and Athru-Derm, all with unique patented delivery systems which are available for distribution through PHD.

Glenmark is one of the leading players in the Indian dermatology segment.